J. Silvio Gutkind
· Department ChairUniversity of California, San Diego · Chemical and Nano Engineering
Active 1984–2025
Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.
About
Translating our scientific discoveries into novel precision treatment options and immunotherapies to prevent and treat cancer.
Research topics
- Biology
- Cancer research
- Genetics
- Internal medicine
- Cell biology
- Medicine
- Oncology
- Surgery
- Pathology
- Immunology
Selected publications
Clinical Cancer Research · 2020 · 203 citations
PURPOSE: To characterize the role of B cells on human papilloma virus (HPV)-associated cancer patient outcomes and determine the effects of radiation and PD-1 blockade on B-cell populations. EXPERIMENTAL DESIGN: HNSCC was used to study the effects of PD-1 blockade and radiotherapy on B-cell activation, differentiation, and clonality including analysis by single-cell RNA-sequencing and B-cell receptor (BCR)-sequencing. Human protein microarray was then used to quantify B-cell-mediated IgG and IgM…
G Protein‐Coupled receptors and heterotrimeric G proteins as cancer drivers
FEBS Letters · 2020 · 140 citations
Senior authorCorrespondingG protein-coupled receptors (GPCRs) and heterotrimeric G proteins play central roles in a diverse array of cellular processes. As such, dysregulation of GPCRs and their coupled heterotrimeric G proteins can dramatically alter the signalling landscape and functional state of a cell. Consistent with their fundamental physiological functions, GPCRs and their effector heterotrimeric G proteins are implicated in some of the most prevalent human diseases, including a complex disease such as cancer tha…
Nature Communications · 2022 · 135 citations
breast cancer cells. Our study suggests LATS as unexpected cancer therapeutic targets, especially for endocrine-resistant breast cancers.
Tipifarnib as a Precision Therapy for <i>HRAS</i> -Mutant Head and Neck Squamous Cell Carcinomas
Molecular Cancer Therapeutics · 2020 · 114 citations
mutations.
Cancer Research · 2025-10-09 · 2 citations
articlePoor infiltration of CD8+ T cells and dysregulation of MHC class I (MHC-I) confer resistance to anticancer immunotherapies. Inhibition of the epigenetic regulator lysine-specific demethylase 1 (LSD1) has been shown to increase CD8+ T-cell infiltration in head and neck squamous cell carcinoma (HNSCC). In this study, we aimed to elucidate the mechanisms of LSD1 inhibition in antitumor immunity in HNSCC to aid in the development of effective therapeutic strategies. LSD1 inhibition in syngeneic and…
Recent grants
Targeting Signaling Vulnerabilities for Oral Cancer Prevention
NIH · $4.7M · 2017–2027
Signal Transduction by PI3K/mTOR
NIH · $2.4M · 2021–2026
Molecular Mechanisms Of Growth Control And Carcinogenesis
NIH · $11.5M
Frequent coauthors
- 341 shared
Vyomesh Patel
Cancer Research Malaysia
- 336 shared
Alfredo Molinolo
- 188 shared
Zhiyong Wang
China Academy of Space Technology
- 178 shared
Panomwat Amornphimoltham
Walailak University
- 141 shared
Joseph A. Califano
University of California, San Diego
- 115 shared
Daniel Martı́n
National Institute on Deafness and Other Communication Disorders
- 104 shared
James F. Rusling
Ollscoil na Gaillimhe – University of Galway
- 95 shared
Hidemi Teramoto
Koujin Hospital
Labs
1-2 sentence research focus
Education
- 2015
Ph.D., Pharmacology
University of California, San Diego
Awards & honors
- American Cancer Society (ACS) Research Professor Award
- Named Chair of the Department of Pharmacology
- Elected to the National Academy of Medicine (NAM)
Similar researchers at University of California, San Diego
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with J. Silvio Gutkind
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup